

## Evaluation of the Effect of Sub-inhibitory Concentrations of Ceftriaxone on Combating Multi-drug Resistant *Staphylococcus aureus*

Received 19<sup>th</sup> April 2024,  
Accepted 9<sup>th</sup> June 2024,  
Published 13<sup>th</sup> July 2024


Amira Omar<sup>1\*</sup>, Tarek E.EL-Banna<sup>1</sup>, Fatma I. Sonbol<sup>1</sup>, Maisra M. El-Bouseary<sup>1\*</sup>

<sup>1</sup>Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

DOI: 10.21608/JAMPR.2024.283820.1066

[jampr.journals.ekb.eg](http://jampr.journals.ekb.eg)

### GRAPHICAL ABSTRACT



### ABSTRACT

*Staphylococcus aureus* is the deadliest of all the common *Staphylococcal* bacteria and is regarded as one of the most common bacteria that cause illnesses. *S. aureus*'s ability to build biofilms and other virulence variables determines whether it can cause superficial or invasive infections. It can also rapidly alter its virulence and metabolic responses in various tissues. Anti-virulent medications that stop the development of biofilms and virulence factors are therefore becoming increasingly necessary. As a result, we focused on an antibiotic that had already been approved and investigated whether changing the dosage would have an impact on *S. aureus* virulence. Most of the studied isolates exhibited a noteworthy decrease in *S. aureus* biofilm and virulence factors production (protease, hemolysin, and coagulase) upon treatment with 1/4 and 1/8 MICs of ceftriaxone, according to the data. It might therefore be regarded as a survival strategy to enhance patient outcomes and reduce germ resistance.

**Keywords:** *Staphylococcus aureus*, Biofilm, Virulence factors, Sub-MIC concentrations, Ceftriaxone

\* Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt.  
Egypt  
E-mail: amira\_omar@pharm.tanta.edu.eg, maisra\_mohamed@pharm.tanta.edu.eg

## 1. INTRODUCTION

*Staphylococcus aureus* is one of the most prevalent infectious microorganisms that cause illness and death worldwide<sup>1,2</sup>. In addition to being a human pathogen, *S. aureus* is a commensal bacterium. About 30 % of people on the Earth have *S. aureus* infection. In addition, it is a major contributor to infections connected to devices, pleuropulmonary, skin and soft tissue, osteoarticular, and infective endocarditis<sup>2</sup>.

*S. aureus* strains generate a multilayered biofilm entrenched in the slime layer and expressing a diverse protein. Antibiotics of various kinds can't treat *S. aureus* infections, especially those linked to their biofilms<sup>3</sup>. The *ica* genes create a polysaccharide intercellular adhesion (PIA), which makes it possible for "biofilm" formation by the bacteria that enables them to grow on both biotic and abiotic surfaces<sup>4</sup>. In addition to protecting the bacteria against various environmental challenges, biofilm stops antibiotics from penetrating and interacting with the bacterial cells<sup>5,6</sup>. Thus, one of the most effective ways to stop the development of antibiotic resistance from occurring in *S. aureus* is to target the biofilm formation<sup>5,6</sup>. Biofilm formation is the mechanism by which *S. aureus* clings to and persists on the native host tissues, such as bone and heart valves, thus causing infective endocarditis and osteomyelitis, respectively<sup>7</sup>. These are in addition to the implanted medical devices, prosthetic joints, artificial heart valves, catheters, and orthopedic implants, which cause severe and enduring infections in hospitalized patients within a healthcare setting<sup>8,9</sup>.

Furthermore, the pathogenic strains of *S. aureus* invade and cause infection by expressing various distinct virulence factors that remarkably participate in the host-pathogen interactions, such as proteases, coagulases, hemolytic toxins (a, b, c, and d), and toxic shock syndrome toxin 1 (TSST1)<sup>10-12</sup>. By releasing toxins and exoenzymes, these virulence factors not only aid in the pathogen's entry into host tissues, immune system evasion, and adherence to host cells, but they also inflict tissue damage<sup>2,9</sup>. The degree of bacterial infection is determined by the expression of these virulence factors, which are regulated by multiple regulatory loci, including the Staphylococcal accessory regulator (sarA) gene and the accessory gene regulator (agr)<sup>11-13</sup>.

In our research, we looked for a medication that could be used to counteract the growth in microbial resistance. To that end, we reexamined the use of ceftriaxone by assessing how it affected bacterial biofilm formation and virulence factors.

## 2. MATERIALS AND METHODS

### 2.1. Chemicals and materials

Nutrient agar, nutrient broth, mannitol salt agar, Mueller-Hinton agar, Luria-Bertani agar, skim milk agar,

Luria-Bertani broth, Tryptic soy broth, ceftriaxone, casein, Trichloroacetic acid, Folin, hydrogen peroxide, glacial acetic acid, methanol, ethyl alcohol, sulfuric acid, phenol, and crystal violet.

### 2.2. Bacterial isolation and identification

The clinical samples of sputum, urine, wound, and blood were collected from patients who were admitted to Tanta University Hospitals, Tanta, Egypt, and cultivated immediately on nutrient agar (NA) after being grown in nutrient broth (NB) (Oxoid, UK). After incubation for 24 h, the recovered bacterial colonies were subjected to traditional identification procedures, such as Gram-staining, growth on mannitol salt agar (MSA) plates, and standard biochemical identification techniques like catalase and coagulase tests<sup>14,15</sup>.

### 2.3. Minimum inhibitory concentrations of the recovered isolates

The minimum inhibitory concentration (MIC) values of ceftriaxone against *S. aureus* isolates were ascertained using the agar dilution technique. Briefly, the molten Mueller-Hinton agar (MHA) was poured into Petri dishes after ceftriaxone (CTR) was added at escalating concentrations (multiple of two, i.e., 0.25, 0.5, 1, 2, 4, 1024 µg/ml) using serial two-fold dilutions. Using an automated pipette, an aliquot of each isolate's prepared suspension was delivered to a specific well in the sterile multi-inoculator seed plate following the record key setup. To prevent the carryover issue, each well in the seed plate was only partially filled. The sterile inoculating rods were used to gently lower the head into the seed plate's well, lift it, and then lower it again onto the agar medium to inoculate the prepared plates. Every rod deposited roughly 1 µl, resulting in a final inoculum of 10<sup>4</sup> CFU/spot per isolate on the agar surface. Every plate was incubated for one night at 37°C.<sup>15,16</sup>

### 2.4. Screening of biofilm production by *S. aureus* isolates

Screening of biofilm formation was performed using 96-well flat bottom plates briefly. The colonies were then homogenized using a vortex mixer and diluted to achieve a turbidity level equivalent to 0.5 McFarland standard in two ml of Tryptic soy broth (TSB) (Oxoid, USA) from overnight cultures. After inoculating each well with 100 µl of the bacterial suspension, the plates were incubated at 37 °C for 24 h. The formed biofilm was fixed using 100% methanol for 20 min. After that, gently cleaning the plates using phosphate-buffered saline (PBS), 100 µl of 0.1% crystal violet (CV) was added to each well and left for 30 min. Following washing the wells with distilled water (DW), the excess CV was removed, and then dissolving CV using a 33% (v/v) glacial acetic acid microtiter reader

(Sunrise TM, TECAN, Switzerland) was used to evaluate the biofilm formation by measuring the OD at 595 nm<sup>17,18</sup>.

## 2.5. Screening for virulence factor expression by *S. aureus* isolates

Using Luria-Bertani agar (LB) plates made with 5% skim milk and 1.5% agar (Oxoid, USA) on them, the tested isolates were grown. After incubating the plates for 48 h at 37°C, we examined the plates to check if any clear zones had formed around the implanted bacteria<sup>20</sup>. To test the hemolytic activity of *S. aureus* isolates, 4% human blood was added to LB agar. The lysis zones surrounding the inoculated bacteria were examined on the plates after 48 h at 28 °C to ascertain their development<sup>19, 20</sup>.

## 2.6. Growth curve of *S. aureus* isolates before and after ceftriaxone treatment

The isolates (n = 13) that produced all virulence factors under investigation were cultivated in LB broth with and without 1/2, 1/4, and 1/8 MICs of ceftriaxone (CTR) at 37°. The OD value for treated and untreated isolates was maintained at 0.3 and samples from each culture were taken every 30 min (at zero time, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, and 420 min.), and the absorbance was measured at 600 nm<sup>21</sup>.

## 2.7. Testing the effect of ceftriaxone at sub-MIC on *S. aureus* biofilm formation

### 2.7.1. Crystal violet microtiter plate assay

The impact of CTR on *S. aureus* isolate biofilm formation was investigated, as prescribed by<sup>22</sup>. Briefly, using a 96-well microtiter plate, the isolates were cultured in TSB for 24 h at 37 °C with and without 1/8 MIC and 1/4 MIC of CTR. The formed biofilm was fixed using 100% methanol for 20 min, dried, and stained with 200 µl of 0.1% CV for 15 min. The plate was then dried after rinsing with water. The stained biofilms were dissolved in 200 µl of 33% (v/v) glacial acetic acid, and then the OD at 595 nm was evaluated using a microplate reader (Sunrise TM, TECAN, Switzerland)<sup>22</sup>. Negative control was used to assess the quality of the process and performed with the same previously mentioned steps with only one exception as no antibiotic or bacteria was added to it. The experiment was performed in triplicate.

### 2.7.2. Phenol-sulfuric acid assay

This assay was conducted to investigate how CTR affected the exo-polysaccharide (EPS) production in the *S. aureus* biofilm matrix. The bacterial isolates were grown for 24 h at 37 °C in LB broth with and without 1/8 and 1/4 MIC

CTR. After incubation, the samples were centrifuged at 8000 g for 10 min., and the pellets were re-suspended in PBS before being centrifuged once again. After centrifugation, an equivalent volume of ethyl alcohol was added to the supernatant. Finally, 1 ml of EPS solution, 5 ml of concentrated sulfuric acid, and 1 ml of cold 5% phenol were carefully mixed. OD was measured at 490 nm, and the percentage of EPS decrease was calculated using the following equation  $\frac{\text{Initial OD} - \text{Final OD}}{\text{Initial OD}} \times 100$ <sup>23</sup>. The experiment was performed in triplicate.

### 2.7.3. Auto aggregation assay

The visual test tube settling method was used to evaluate the sedimentation rate, which is in turn related to bacterial auto-aggregation; therefore, we used it to evaluate the impact of CTR on *S. aureus* auto-aggregation. Briefly, 5 test tubes of overnight cultures with and without 1/4 and 1/8 MIC of CTR in LB broth were adjusted at 600 nm to the same optical density and then vigorously vortexed. The OD was measured at (0 h, 2 h, 4 h, 8 h, and 24 h) by taking one time from each test tube superficial supernatant<sup>24</sup>.

## 2.8. Testing of sub-MIC of ceftriaxone on virulence factors

### 2.8.1. Protease production

The bacterial isolates were screened on skimmed milk for protease production after being cultivated in LB broth with and without CTR for 24 h at 37 °C. After incubation, the broth was centrifuged at 5000 rpm and then filtered using a Millipore filter (0.45 µm). The skim milk agar plates' wells were filled with bacterial supernatants (100 µl). After incubation for 24 h at 37 °C, the diameter of the formed lysis zones developed around the wells was measured using a calibrated ruler<sup>16, 25</sup>. Moreover, protease assay using casein as a substrate was conducted. A bacterial suspension in LB broth was prepared with and without CTR and incubated for 24 h at 37 °C. After incubation, 1 ml of the supernatant obtained after centrifugation and filtration was added to 1 ml of 0.05 M phosphate buffer and 0.1 M NaOH containing 2% casein and then incubated at 37 °C for 10 min. The reaction was stopped by adding 2 ml of 0.4 M trichloro-acetic acid (TCA) and incubated at 37 °C for 30 min. The obtained solution was centrifuged at 5000 rpm for 15 min. Finally, 3 ml of filtrate was mixed with 5 ml of Na<sub>2</sub>CO<sub>3</sub> and 2 ml of Folin, and then the absorbance was measured at 660 nm<sup>20</sup>. Negative control was performed as the same as the previously mentioned steps expect only the first step as LB broth was used without CTR and without bacteria. The experiment was performed in triplicate.

### 2.8.2. Hemolysin production

Using both qualitative and quantitative approaches, hemolysin production was found to be impacted by CTR. In the qualitative approach, 180  $\mu$ l of LB broth, either with or without CTR, was mixed with bacterial overnight culture (20  $\mu$ l) or incubated at 37 °C. After incubation for 18 h, the samples were streaked on human blood agar plates for 24 h at 37 °C. The resulting clear zone surrounding the inoculated bacterium was observed. In the quantitative approach, *S. aureus* strains were inoculated in LB broth with and without CTR. After incubation, centrifuging, and filtration of the resulting supernatant, 600  $\mu$ l of a 2% red blood cell (RBC) suspension was mixed with 600  $\mu$ l of the supernatant and incubated for 2 h at 37 °C. After incubation, the obtained suspension was centrifuged for 8 min. at 4 °C at 10,000 g. Hemoglobin release was recorded by measuring the absorbance percentage of cells lysed was calculated as follows: The percentage of cells lysed =  $[(X-B) / (T-B)] \times 100$  B is a negative control corresponding to RBCs incubated with 600  $\mu$ l of sterile LB. T is a positive control corresponding to the total lysis obtained by incubating RBCs in LB supplemented with 0.1% SDS. X is the absorbance value of the sample analyzed at 540 nm<sup>25,26</sup>.

### 2.8.3. Coagulase production

The bacterial supernatants were double-fold diluted serially in 96-well, round-bottom microtiter plates using brain heart infusion (BHI) (Oxoid, USA) broth. All wells received 100  $\mu$ l of a citrated plasma solution (20% v/v) before being combined with serial dilutions of CTR. The plates were incubated at 37 °C and observed after 4 h of incubation. The maximum dilution at which plasma coagulation was observed, or the titer, was measured (the titer, which is the reciprocal of the greatest dilution, shows plasma coagulation). Negative control treatments were used by combining citrated rabbit plasma with BHI broth. The experiment was repeated three times<sup>27</sup>.


## 2.9. Statistical analysis

One-way analysis of variance (ANOVA), the T-test, and a significance cut-off of 0.05 for p-value were used to examine the data. Every assay was conducted three times, and the results were expressed using the mean standard deviation ( $\pm$ SD).

## 3. RESULTS

### 3.1. Bacterial isolates

Regarding the sources of the clinical samples, most bacterial isolates were recovered from sputum (n = 41), urine (n = 19), wound (n = 7), and blood (n = 3) as shown in **Fig. 1**.



**Figure. 1.** Sources of the recovered isolates.

### 3.2. Determination of minimum inhibitory concentrations of the Ceftriaxone


The MICs of CTR were determined against the bacterial isolates (n = 70). Ceftriaxone MICs ranged from 8  $\mu$ g/ml to 256  $\mu$ g/ml. Most of the isolates (n = 36) have MIC = 8  $\mu$ g/ml, followed by MIC = 16  $\mu$ g/ml (n = 15), then MIC = 256  $\mu$ g/ml (n = 8), then MIC = 64  $\mu$ g/ml (n = 4), and finally MIC = 128  $\mu$ g/ml (n = 1).

### 3.3. Bacterial growth rate in the presence of sub-MIC of Ceftriaxone

The effect of CTR at 1/2, 1/4, and 1/8 MICs on the bacterial growth of the selected isolates (n = 13) was tested at different intervals. The obtained data showed that 1/2 markedly affected bacterial growth, 1/4 MIC showed lower activity, and the effect of 1/8 MIC was negligible as shown in **Fig. 2**.

#### 3.4.1. Crystal violet microtitration assay

The biofilm formation of the selected bacterial isolates (n = 13) was significantly affected ( $p < 0.05$ ), as shown in **Fig. (3)**, and demonstrated in **Table (1)**. In the presence of CTR, most isolates showed a reduction in biofilm formation at both 1/4 and 1/8 MIC treatments. The recorded reduction of CTR ranged from -34 to 63 %, and 1.6 to 66 %, with 1/8 and 1/4 MICs treatments, respectively. The previous percentage reduction calculated using the following equation =  $(OD \text{ untreated} - OD \text{ treated}) / OD \text{ untreated} * 100$



**Figure. 3.** Crystal violet microtitration assay. Revealing the reduction occurred with treatment in most of the bacterial isolates.





Figure.2. Growth curves of the selected 13 *S. aureus* isolates.

**Table 1.** Percent (%) of biofilm reduction in the presence of sub-MIC of Ceftriaxone. CTR: Ceftriaxone. The asterisks represents the statistical significance ( $p < 0.05$ ).

Isolate Code	% Reduction in biofilm formation with sub-MIC of CTR		Isolate code	% Reduction in biofilm formation with sub-MIC of CTR	
	1/8	1/4		1/8	1/4
S 11	27 <sup>***</sup>	63 <sup>***</sup>	S 74	59 <sup>***</sup>	62 <sup>***</sup>
S 14	10 <sup>***</sup>	21 <sup>***</sup>	W 7	15 <sup>***</sup>	38 <sup>***</sup>
S 33	45 <sup>***</sup>	62 <sup>***</sup>	U110	13 <sup>***</sup>	19 <sup>***</sup>
S 39	63 <sup>***</sup>	66 <sup>***</sup>	B 89	1	37 <sup>***</sup>
S 51	25 <sup>***</sup>	33 <sup>***</sup>	S 8	-34 <sup>***</sup>	1.6
S 71	61 <sup>***</sup>	65 <sup>***</sup>	S 69	14 <sup>***</sup>	24 <sup>***</sup>
S 80	5 <sup>***</sup>	53 <sup>***</sup>			

### 3.4.2. Phenol-sulfuric acid method for assessment of exo-polysaccharide formation

Further investigation on the effect of CTR on biofilm formation was done by studying its effect on matrix formation (EPS). There was a significant ( $p < 0.05$ ) reduction in EPS formation in most of the tested bacterial isolates that may be up to 85% after 1/4 MIC treatment and up to 80% with 1/8 MIC treatment (Fig.4)



**Figure.4.** Effect of CTR on EPS formation. (A) The phenol sulphuric acid method revealed the reduction in EPS formation that occurred in the majority of the tested isolates. (B) Chart showing the change in OD values concerning EPS formation.

### 3.4.3. Auto aggregation measurement









The impact of 1/8 and 1/4 MIC of CTR on bacterial auto-aggregation was determined by measuring the sedimentation rate. From OD measurement, we observed that sub-MIC of CTR decreased the rate of bacterial auto-aggregation in most of the tested isolates, and this was highly correlated with the reduction in bacterial biofilm formation. (Fig. 5).

### 3.5. The impact of ceftriaxone at sub-MIC on S. aureus virulence


The results of sub-MIC of CTR on the production of protease, hemolysis, and coagulase were evaluated.

#### 3.5.1. Protease production


The effect of sub-MIC of CTR on S. aureus protease production was evaluated. The treated S. aureus isolates were significantly ( $p < 0.05$ ) affected by CTR treatment as previously shown in Fig. 6. Exposure to CTR at 1/4 and 1/8 MICs caused a reduction in protease production by 28-100 % and -33-44 %, respectively.







**Figure 5.** Auto aggregation measurement through measuring the % reduction of initial OD value for 13 isolates



**Figure 6.** A representative result about the effect of CTR at sub-MIC on *S. aureus* protease production (A) The most common result that was detected with treatment. (B) Percent reduction of protease production with different concentrations of CTR. The error bars indicate standard deviations. The asterisks represent statistical significance ( $P < 0.05$ ).



### 3.5.2. Hemolysin production

The hemolytic activity of *S. aureus* isolates was detected with and without treatment by 1/4 and 1/8 MICs of CTR. The degree of hemolysis was determined using the spectrophotometric method. The exposure to CTR at 1/4 and 1/8 MICs caused a reduction in hemolysin production by 18-100 % and -32-46 % (Fig. 7).




Fig. 7. Percent reduction in hemolysin production with different concentrations of CTR. The error bars indicate standard deviations. The asterisks represent statistical significance ( $P < 0.05$ ).

### 3.5.3. Coagulase production

Through the determination of the coagulation titer, the effect of treatment with sub-MIC of CTR on coagulase production was evaluated. Results showed that CTR at 1/4 and 1/8 MICs significantly ( $p < 0.05$ ) affected coagulase production as seen in Fig. 8. Most bacterial isolates showed a reduction in the coagulation titer that in some cases reached 100% reduction.

## 4. DISCUSSION

The Gram-positive *Staphylococcus aureus* germs cause a broad range of clinical illnesses. This bacterium is frequently the main source of infections in both hospital and community settings. On healthy skin, *S. aureus* often does not cause infections, but if it gets into the circulation or internal tissues, it can cause several potentially dangerous illnesses<sup>28, 29</sup>.

The rise of multi-drug-resistant bacteria, such as Methicillin-resistant *Staphylococcus aureus* (MRSA), makes their treatments more difficult. MRSA has become a common source of infections acquired in hospitals as well as in the population. Now, MRSA causes ten times as many infections as all the multi-drug-resistant (MDR) Gram-negative bacteria. MRSA is one of the twelve priority

infections that the World Health Organization (WHO) has identified as being dangerous to human health<sup>30, 31</sup>.




Fig. 8. A representative result about the effect of CTR at sub-MIC on *S. aureus* coagulase production. (A) Decrease of coagulation titer with sub-MIC treatment. (B) Percent of the reduction in titer of coagulase after CTR treatment. The error bars indicate standard deviations. The asterisks represent statistical significance ( $P < 0.05$ ).

Apart from the conventional resistance mechanisms of *S. aureus*, it is characterized by its capacity to persist in the biofilm state on biotic and abiotic surfaces<sup>32</sup>. This trait makes *S. aureus* among the most frequent reasons for people to get infections.<sup>30, 31</sup> A biofilm is a collection of linked cells from microorganisms that are covered in a matrix made of proteins, various organic compounds, and extracellular polymeric substances (EPSs)<sup>33</sup>. Polysaccharide intercellular adhesion (PIA), which is generated by the intercellular adhesion (ICA) locus, is a significant constituent of *S. aureus* biofilms. Biofilm production is also connected to the expression of the ICA gene. The bacteria that form biofilms are up to 1000 times less sensitive to antibiotics, which makes them considerably harder to cure<sup>34, 35</sup>.

In this study, we tried to indicate the impact of the sub-MIC of CTR on *S. aureus* biofilm production. From our study, it was detected that CTR at 1/8 and 1/4 MIC caused a reduction in biofilm formation, which ranged from -34 to 63% and from 1.6 to 66%, respectively. Moreover, the impact of CTR at various concentrations on the *S. aureus* biofilm matrix was investigated by measuring EPS formation using the phenol-sulfuric acid assay and through OD measurements. The reduction in color intensity in most of the tested isolates was detected, which indicated that there was a decrease in EPS formation by sub-MIC treatment.

Moreover, it was revealed that there was a significant

reduction in bacterial auto-aggregation in most of the tested isolates, which was highly correlated to their reduction in biofilm formation except for the S8 isolate. Additionally, the pathogenicity of an infection caused by *S. aureus* is determined by its virulence factors, which include toxins, secreted enzymes (i.e., lipase and protease), and adhesins (i.e., fibronectin-binding protein and protein A).

Therefore, the ability of an antibiotic to inhibit the release of virulence factors by a bacterium may be just as crucial to the effectiveness of antibiotic therapy for infections caused by *S. aureus* as its bacteriostatic or bactericidal properties<sup>2, 36, 37</sup>.

In this study, the impact of CTR on *S. aureus* virulence factor production was studied. The obtained results indicated that there was a significant reduction in protease production that ranged from 28–100% and -33–44% after exposure to 1/4 MIC and 1/8 MIC, respectively. Ceftriaxone also reduced hemolysin production that ranged from 18 to 100% and from -32 to 46% with 1/4 and 1/8 MIC treatments, respectively, which was detected using the spectrophotometric method from which the amount of released hemoglobin was calculated. This was directly proportional to hemolysin production. Furthermore, coagulase production was significantly reduced after treatment with 1/4 and 1/8 MIC of CTR, which ranged from 0-100% and -50-100%, respectively.

El-Mowafy et al., findings corroborated with our results, showing that modest  $\beta$ -lactam dosages drastically altered the Quorum sensing QS signals and reduced the virulence factors<sup>38</sup>. Moreover, Caixeta et al., study showed that sub-MICs of  $\beta$ -lactam suppressed the virulence gene expression and biofilm formation<sup>39</sup>.

Additionally, Kumar demonstrated how several  $\beta$ -lactams had anti-virulence and anti-QS properties<sup>40</sup>. A previous study conducted by Viedma et al., showed that the relative levels of agr locus expression were impacted by oxacillin at sub-MIC, which affected the virulence and biofilm formation<sup>41</sup>. Previous studies reported that, when compared to the untreated control, the isolates treated with a  $\beta$ -lactam antibiotic at sub-MIC exhibited lower levels of hemolysis<sup>42, 43</sup>.

Stoitsova et al., study revealed that the various  $\beta$ -lactam antibiotics at various sub-MIC doses affected the formation of biofilms in different ways; either by inducing or inhibiting the growth of the distinct bacterial strains<sup>44</sup>.

According to Frank et al., the cell wall-active antibiotics either did not affect *S. aureus* biofilm formation or had an inhibitory effect at sub-MIC doses<sup>45</sup>. In accordance, Majidpour et al., study except for a single strain that showed an increase in biofilm formation, *S. aureus* exposed to sub-MICs of oxacillin significantly reduced the production of biofilms<sup>46</sup>.

Moreover, García-Torrico et al., revealed that sub-MIC

caused irreversible physiological alterations, including delayed growth, aggregation, modification, and changes in outer membrane proteins (OMPs) and lipopolysaccharide (LPS) profiles, resulting in a complete diminution of *Yersinia ruckeri*'s virulence<sup>47</sup>. A previous study revealed that *Pseudomonas aeruginosa* exposed to  $\beta$ -lactam antibiotics at sub-MIC increased extracellular toxins production which in turn led to worsening in the *Pseudomonas aeruginosa* infection model<sup>48</sup>.

Also, it was reported previously by Hodille et al., that treatment with sub-MIC of  $\beta$ -lactams has the potential to increase Staphylococcal pathogenicity and worsen the infection<sup>49</sup>. The synthesis of  $\alpha$ -toxin, PVL toxin, enterotoxins, toxic shock syndrome toxin (TSST), and LukED is induced by the  $\beta$ -lactam antibiotics at non-lethal concentrations, which led to therapeutic modifications and worse outcomes<sup>49</sup>.

## 5. CONCLUSION

The rise in microorganism resistance makes it more difficult for the patient to heal fully, ultimately worsening their prognosis. It is highly desirable to find new drugs rather than conventional ones to reduce the severity of the infection and compact bacterial resistance, as the ability of bacteria to form biofilms and secrete various virulence factors is a crucial factor in establishing the infection and reducing bacterial sensitivity. It was discovered that the current antibiotic, when taken at its 1/4 or 1/8 MICs, significantly reduced the development of both biofilm and virulence factors in the majority of the studied bacterial isolates without the need for studying their safety as it had been used for several decades, but further studies may be required to confirm the inhibitory effect of sub-MIC and exclude any undesired results that may occur, and until that, it must be taken at its recommended dose.

## AUTHOR'S CONTRIBUTIONS

Conceptualization: Tarek El-Banna, Fatma Sonbol, and Maisra El-Bouseary; Data curation: Amira Omar and Maisra El-Bouseary; Formal analysis: Amira Omar, Tarek El-Banna, Fatma Sonbol, and Maisra El-Bouseary; Methodology: Amira Omar, Tarek El-Banna, Fatma Sonbol, and Maisra El-Bouseary; Visualization: Tarek El-Banna, Fatma Sonbol, and Maisra El-Bouseary; Writing – original draft: Amira Omar and Maisra El-Bouseary; Writing – review & editing: Amira Omar, Fatma Sonbol, and Maisra El-Bouseary. All authors have read and agreed to the published version of the manuscript.

## FUNDING SOURCE:

This research received no external funding.

**ACKNOWLEDGMENTS:**

Non-applicable.

**CONFLICTS OF INTEREST:**

The authors declare no conflicts of interest.

**6. REFERENCES**

- Esposito S, Blasi F, Curtis N, Kaplan S, Lazzarotto T, Meschiari M, Bassetti M. New antibiotics for Staphylococcus aureus infection: an update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-infective Therapy (SITA). *Antibiotics*. 2023; 12(4):742. doi:10.3390/antibiotics12040742
- Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. *Virulence*. 2021; 12(1):547–569. doi:10.1080/21505594.2021.1878688
- Joshi, S., Lahiri, D., Ray, R. R., & Davoodbasha, M. (Eds.). *Microbial Biofilms: Challenges and advances in metabolomic Study*. (2023).
- Aboelnaga N, Elsayed SW, Abdelsalam NA, et al. Deciphering the dynamics of methicillin-resistant Staphylococcus aureus biofilm formation: from molecular signaling to nanotherapeutic advances. *Cell Commun Signal*. 2024; 22(1):188. doi:10.1186/s12964-024-01511-222.
- Lade H, Park JH, Chung SH, et al. Biofilm Formation by Staphylococcus aureus Clinical Isolates is Differentially Affected by Glucose and Sodium Chloride Supplemented Culture Media. *J Clin Med*. 2019; 8(11):1853. doi:10.3390/jcm8111853
- Verderosa AD, Totsika M, Fairfull-Smith KE. Bacterial Biofilm Eradication Agents: A Current Review. *Front Chem*. 2019; 7:824. doi:10.3389/fchem.2019.00824
- Datta S, Nag S, Roy DN. Biofilm-producing antibiotic-resistant bacteria in Indian patients: a comprehensive review. *Curr Med Res Opin*. 2024; 40(3):403–422. doi:10.1080/03007995.2024.2305241.
- Hogan S, O’Gara JP, O’Neill E. Novel treatment of Staphylococcus aureus device-related infections using fibrinolytic agents. *Antimicrob. Agents Chemother*. 2018;62:10.1128/aac.02008-17. doi:10.1128/aac.02008-17.
- Kadkhoda H, Ghalavand Z, Nikmanesh B, Kodori M, Hourri H, Maleki DT, Bavandpour AK, Eslami G. Characterization of biofilm formation and virulence factors of Staphylococcus aureus isolates from pediatric patients in Tehran, Iran. *J. Basic Med. Sci*. 2020; 23(5):691–698. doi:10.22038/ijbms.2020.36299.8644.
- Blomberg, M. T., Moriarty, F. T., Boraschi, D., & Sobacchi, Copen-access edited by. *Women in Cytokines and Soluble Mediators in Immunity*. (2024). 228.
- Abbas HA, Atallah H, El-Sayed MA, El-Ganiny AM. Diclofenac mitigates virulence of multidrug-resistant Staphylococcus aureus. *Arch. Microbiol*. 2020; 202(10):2751–2760. doi:10.1007/s00203-020-01992-y.
- Chen J, Zhou H, Huang J, Zhang R, Rao X. Virulence alterations in Staphylococcus aureus upon treatment with sub-inhibitory concentrations of antibiotics. *J Adv Res*. 2021; 31:165–175. doi:10.1016/j.jare.2021.01.008.
- Taj Z, Chattopadhyay I. Staphylococcus aureus virulence factors and biofilm components: synthesis, structure, function, and inhibitors. In: Busi S, Prasad R, eds. *ESKAPE Pathogens: Detection, Mechanisms and Treatment Strategies*. Springer; 2024. doi:10.1007/978-981-99-8799-3\_8.
- Mirzaie A, Peirovi N, Akbarzadeh I, Moghtaderi M, Heidari F, Yeganeh FE, Noorbazargan H, Mirzazadeh S, Bakhtiari R. Preparation and optimization of ciprofloxacin-encapsulated noisome: A new approach for enhanced antibacterial activity, biofilm inhibition, and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus. *Bioorg. Chem*. 2020; 103. doi:10.1016/j.bioorg.2020.104231.
- Gebremedhin EZ, Ararso AB, Borana BM, et al. Isolation and Identification of Staphylococcus aureus from Milk and Milk Products, Associated Factors for Contamination, and Their Antibiogram in Holeta, Central Ethiopia. *Vet Med Int*. 2022; 2022:6544705. Published 2022 May 6. doi:10.1155/2022/6544705.
- Balouiri M, Sadiki M, Ibsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. *J Pharm Anal*. 2016; 6(2):71-79. doi:10.1016/j.jpha.2015.11.005.
- Farha AK, Yang QQ, Kim G, Zhang D, Mavumengwana V, Habimana O, Li HB, Corke H, Gan RY. Inhibition of multidrug-resistant foodborne Staphylococcus aureus biofilms by a natural terpenoid (+)-nootkatone and related molecular mechanism. *Food Control*. 2020; 112. doi:10.1016/j.foodcont.2020.107154.
- Idrees M, Sawant S, Karodia N, Rahman A. Staphylococcus aureus Biofilm: Morphology, Genetics, Pathogenesis and Treatment Strategies. *Int J Environ Res Public Health*. 2021; 18(14):7602. doi:10.3390/ijerph18147602.
- Adame-Gómez R, Castro-Alarcón N, Vences-Velázquez A, et al. Genetic Diversity and Virulence Factors of S. aureus Isolated from Food, Humans, and Animals. *Int J Microbiol*. 2020; 2020:1048097. Published 2020 Aug 27. doi:10.1155/2020/1048097.
- Cupp-Enyard C. Sigma's Non-specific Protease Activity Assay - Casein as a Substrate. *J Vis Exp*. 2008 ;(19):899. doi:10.3791/899.
- Ganesh PS, Veena K, Senthil R, et al. Biofilm-Associated Agr and Sar Quorum Sensing Systems of Staphylococcus aureus Are Inhibited by 3-Hydroxybenzoic Acid Derived from Illicium verum. *ACS Omega*. 2022; 7(17):14653-14665. doi:10.1021/acsomega.1c07178.
- Saeloh D, Visutthi M. Efficacy of Thai Plant Extracts for Antibacterial and Anti-Biofilm Activities against

- Pathogenic Bacteria. *Antibiotics (Basel)*. 2021; 10(12):1470. doi:10.3390/antibiotics10121470.
23. Tania S, Anowara B, Humaira A. Effect of pesticides on exopolysaccharide (EPS) production, antibiotic sensitivity, and phosphate solubilization by rhizobial isolates from *Sesbania bispinosa* in Bangladesh. *Afr. J. Agric. Res.* 2019; 14(34):1845–1854. doi:10.5897/ajar2019.14304.
  24. Valliammai A, Sethupathy S, Priya A, Selvaraj A, Bhaskar JP, Krishnan V, Pandian SK. 5-Dodecanolide interferes with biofilm formation and reduces the virulence of Methicillin-resistant *Staphylococcus aureus* (MRSA) through upregulation of agr system. *Sci Rep.* 2019; 9(1). doi:10.1038/s41598-019-50207-y.
  25. Saleh MM, Yousef N, Shafik SM, Abbas HA. Attenuating the virulence of the resistant superbug *Staphylococcus aureus* bacteria isolated from neonatal sepsis by ascorbic acid, dexamethasone, and sodium bicarbonate. *BMC Microbiol.* 2022; 22(1):268. doi:10.1186/s12866-022-02684-x.
  26. Peterson MM, Mack JL, Hall PR, et al. Apolipoprotein B Is an innate barrier against invasive *Staphylococcus aureus* infection. *Cell Host Microbe.* 2008;4(6):555-566. doi:10.1016/j.chom.2008.10.001.
  27. Yanagihara K, Morinaga Y, Nakamura S, et al. Subinhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant *Staphylococcus aureus* coagulase in vitro and in vivo. *J Antimicrob Chemother.* 2008; 61(3):647-650. doi:10.1093/jac/dkm507.
  28. Howden BP, Giulieri SG, Wong Fok Lung T, et al. *Staphylococcus aureus* host interactions and adaptation. *Nat Rev Microbiol.* 2023; 21(6):380-395. doi:10.1038/s41579-023-00852-y.
  29. Kwiecinski JM, Horswill AR. *Staphylococcus aureus* bloodstream infections: pathogenesis and regulatory mechanisms. *Curr Opin Microbiol.* 2020; 53:51-60. doi:10.1016/j.mib.2020.02.005.
  30. Craft KM, Nguyen JM, Berg LJ, Townsend SD. Methicillin-resistant *Staphylococcus aureus* (MRSA): Antibiotic resistance and the biofilm phenotype. *MedChemComm.* 2019; 10(8):1231–1241. doi:10.1039/c9md00044e.
  31. Mlynarczyk-Bonikowska B, Kowalewski C, Krolak-Ulinska A, Marusza W. Molecular Mechanisms of Drug Resistance in *Staphylococcus aureus*. *Int J Mol Sci.* 2022; 23(15):8088. Published 2022 Jul 22. doi:10.3390/ijms23158088.
  32. Yu J, Han W, Xu Y, et al. The biofilm-producing ability of methicillin-resistant *Staphylococcus aureus* clinically isolated in China [Preprint]. *Res. Sq.* 2024. doi:10.21203/rs.3.rs-3852952/v1.
  33. Ali N, Abbas SAAA, Sharif L, Shafiq M, Kamran Z, Haseeb M, Shahid MA. Microbial extracellular polymeric substance and impacts on soil aggregation. In *Bacterial Secondary Metabolites: Synthesis and Applications in Agroecosystem.* 2024:221–237. doi:10.1016/B978-0-323-95251-4.00021-1.
  34. Alonso VPP, Furtado MM, Iwase CHT, Brondi-Mendes JZ, Nascimento MDS. Microbial resistance to sanitizers in the food industry: review. *Crit Rev Food Sci Nutr.* 2024; 64(3):654-669. doi:10.1080/10408398.2022.2107996.
  35. Nguyen HTT, Nguyen TH, Otto M. The staphylococcal exopolysaccharide PIA – Biosynthesis and role in biofilm formation, colonization, and infection. *Comput Struct Biotechnol J.* 2020; 18:3324–3334. doi:10.1016/j.csbj.2020.10.027.
  36. Ahmad-Mansour N, Loubet P, Pouget C, et al. *Staphylococcus aureus* Toxins: An Update on Their Pathogenic Properties and Potential Treatments. *Toxins (Basel).* 2021; 13(10):677. doi:10.3390/toxins13100677.
  37. Liu H, Xu T, Xue Z, Huang M, Wang T, Zhang M, Yang R, Guo Y. *ACS Infect. Dis.* 2024; 10(2):350-370. doi:10.1021/acinfeddis.3c00647.
  38. El-Mowafy SA, Abd El Galil KH, Habib EE, Shaaban MI. Quorum sensing inhibitory activity of sub-inhibitory concentrations of  $\beta$ -lactams. *Afr Health Sci.* 2017; 17(1):199-207. doi:10.4314/ahs.v17i1.25.
  39. Caixeta Magalhães Tibúrcio AA, Paiva AD, Pedrosa AL, Rodrigues WF, Bernardes da Silva R, Oliveira AG. Effect of sub-inhibitory concentrations of antibiotics on biofilm formation and expression of virulence genes in penicillin-resistant, ampicillin-susceptible *Enterococcus faecalis*. *Heliyon.* 2022; 8(10):e11154. doi:10.1016/j.heliyon.2022.e11154.
  40. Kumar L, Brenner N, Brice J, Klein-Seetharaman J, Sarkar SK. Cephalosporins target quorum sensing and suppress virulence of *Pseudomonas aeruginosa* in *Caenorhabditis elegans* infection model. *bioRxiv.* 2020; 2020.05.15.097790. doi:10.1101/2020.05.15.097790.
  41. Viedma E, Pérez-Montarelo D, Villa J, et al. Sub-inhibitory concentrations of oxacillin modify the expression of agr locus in *Staphylococcus aureus* clinical strains belonging to different clonal complexes. *BMC Infect Dis.* 2018; 18(1):177. doi:10.1186/s12879-018-3088-7.
  42. Asadi S, Nayeri-Fasaei B, Zahraei-Salehi T, Yahya-Rayat R, Shams N, Sharifi A. Antibacterial and anti-biofilm properties of carvacrol alone and in combination with cefixime against *Escherichia coli*. *BMC Microbiol.* 2023; 23(1):55. doi:10.1186/s12866-023-02797-x.
  43. Derakhshan S, Ahmadi S, Ahmadi E, Nasseri S, Aghaei A. Characterization of *Escherichia coli* isolated from urinary tract infection and association between virulence expression and antimicrobial susceptibility. *BMC Microbiol.* 2022; 22(1):89. doi:10.1186/s12866-022-02506-0.
  44. Stoitsova SR, Paunova-Krasteva TS, Borisova DB. Modulation of Biofilm Growth by Sub-Inhibitory Amounts of Antibacterial Substances. *Microbial Biofilms - Importance and Applications.* 2016. doi:10.5772/62939.

45. Frank KL, Reichert EJ, Piper KE, Patel R. In vitro effects of antimicrobial agents on planktonic and biofilm forms of *Staphylococcus lugdunensis* clinical isolates. *Antimicrob Agents Chemother.* 2007; 51(3):888-895. doi:10.1128/AAC.01052-06.
46. Majidpour A, Fathizadeh S, Afshar M, et al. Dose-Dependent Effects of Common Antibiotics Used to Treat *Staphylococcus aureus* on Biofilm Formation. *Iran J Pathol.* 2017; 12(4):362-370.
47. García-Torrico AI, Guijarro JA, Cascales D, Méndez J. Changes in physiology and virulence during the selection of resistant *Yersinia ruckeri* mutants under subinhibitory cefotaxime concentrations. *J Fish Dis.* 2019; 42(12):1687-1696. doi:10.1111/jfd.13086.
48. Geers TA, Baker NR. The effect of sublethal levels of antibiotics on the pathogenicity of *Pseudomonas aeruginosa* for tracheal tissue. *J Antimicrob Chemother.* 1987; 19(5):569-578. doi:10.1093/jac/19.5.569.
49. Hodille E, Beraud L, Périan S, et al. Sub-Inhibitory Concentrations of Oxacillin, but Not Clindamycin, Linezolid, or Tigecycline, Decrease Staphylococcal Phenol-Soluble Modulin Expression in Community-Acquired Methicillin-Resistant *Staphylococcus aureus*. *Microbiol Spectr.* 2022; 10(1):e0080821. doi:10.1128/spectrum.00808-21